AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01386970
Drug: zidovudine 300mg and lamivudine 150mg as Combivir
RxNorm normalized name: lamivudine 150 MG / zidovudine 300 MG [Combivir]
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
Trial: NCT01523977
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally, daily days 1-32 per assigned dose level
Trial: NCT01523977
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m2/day orally 3 x daily days 4-32
Trial: NCT01523977
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m2 IV daily on days 4, 11, 18, and 25
Trial: NCT01523977
Drug: PEG-Asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2,500 U/m2 IV 1 x daily on days 5 and 18
Trial: NCT00406497
Drug: Difluprednate Ophthalmic Emulsion
RxNorm normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01523977
Drug: Dexrazoxane
RxNorm normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m2 IV on days 4 and 5
Trial: NCT03020940
Drug: Cefuroxime Axetil Dispersible Tablets
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults
Trial: NCT02511223
Drug: OLAPARIB
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
Trial: NCT01149668
Drug: PCI-24781
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
Trial: NCT01049542
Drug: Astressin 2B
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
Trial: NCT00221468
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
Trial: NCT00015834
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00015834
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01206088
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of nilotinib as 2nd line
Trial: NCT01458041
Drug: Iloprost (Ilomedin, BAYQ6256)
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription and treatment of Iloprost will be decided by physicians
Trial: NCT00742144
Drug: ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
Trial: NCT00003021
Drug: bizelesin
RxNorm normalized name: Bizelesin
DrugBank: Bizelesin (DB12352)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03472261
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Dysport
Trial: NCT03835949
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humanized monoclonal antibody to PD-L1
Trial: NCT00217659
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00217659
Drug: goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02456363
Drug: NSAIDs and sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
Trial: NCT00616538
Drug: Fluticasone Propionate 0.05%
RxNorm normalized name: FLUTICASONE PROPIONATE 0.05% CREAM
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical mid-strength steroid
Trial: NCT01727024
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium via Respimat® device once a day
Trial: NCT01727024
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol via Breezhaler® device once a day
Trial: NCT02549924
Drug: Resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
Trial: NCT00918736
Drug: sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
Trial: NCT02204475
Drug: Grazoprevir/Elbasvir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
Trial: NCT02204475
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
Trial: NCT02204475
Drug: PegIntron
RxNorm normalized name: PegIntron
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
Trial: NCT02204475
Drug: Ribavarin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
Trial: NCT03642132
Drug: Chemotherapy + avelumab followed by avelumab + talazoparib
RxNorm normalized name: Avelumab
DrugBank: Talazoparib (DB11760)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib
Trial: NCT03642132
Drug: Chemotherapy followed by talazoparib maintenance
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib
Trial: NCT02263677
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
Trial: NCT01103375
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01103375
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01159652
Drug: zaleplon
RxNorm normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg
Trial: NCT01159652
Drug: zolpidem extended release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg
Trial: NCT00383929
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 32mg oral
Trial: NCT00383929
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral
Trial: NCT00383929
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg oral
Trial: NCT00381134
Drug: losartan 100 mg orally once daily
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04525066
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Trial: NCT02925650
Drug: Posiphen
RxNorm normalized name: Posiphen
DrugBank: Posiphen (DB15317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solid dosage form capsule
Trial: NCT01258751
Drug: PF-05212377
RxNorm normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
Trial: NCT02268214
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets
Trial: NCT02268214
Drug: Placebo for dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets
Trial: NCT00457795
Drug: brimonidine 0.1% (Alphagan® P)
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
Trial: NCT01352871
Drug: lipopolysaccharide
RxNorm normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipopolysaccharide 2ng/kg intravenously
Trial: NCT00912756
Drug: cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/day BID
Trial: NCT03642132
Drug: Chemotherapy + bevacizumab followed by bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab
Trial: NCT03718559
Drug: Edoxaban Monotherapy
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
Trial: NCT03718559
Drug: Edoxaban plus Single Antiplatelet Agent
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
Trial: NCT01153659
Drug: E3810
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RAB ER 50 mg capsule once per day on Days 1-5
Trial: NCT01153659
Drug: Aciphex (rabeprazole)
RxNorm normalized name: Aciphex
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
Trial: NCT01153659
Drug: Nexium (esomeprazole)
RxNorm normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
Trial: NCT04122339
Drug: MAX-10181
RxNorm normalized name: Bronkaid Max
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Trial: NCT00209560
Drug: fospropofol disodium
RxNorm normalized name: Fospropofol disodium
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04498260
Drug: Local steroid - triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (triamcinolone acetonide)
Trial: NCT00805857
Drug: Tipranavir
RxNorm normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02101710
Drug: Elantan SR 60 mg
RxNorm normalized name: Elantan
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Trial: NCT02101710
Drug: Imdur SR 60 mg
RxNorm normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Trial: NCT01158170
Drug: Erlotinib /Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
Trial: NCT00016406
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00233675
Drug: GABITRIL (tiagabine hydrochloride; CEP-6671)
RxNorm normalized name: tiagabine hydrochloride 12 MG [Gabitril]
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00036608
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00233454
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
Trial: NCT02317744
Drug: Naltrexone and bupropion combination
RxNorm normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01363349
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01958489
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02269085
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I.
Trial: NCT02269085
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I.
Trial: NCT00741026
Drug: Olanzapine 10 mg po qhs for 3 days
RxNorm normalized name: olanzapine 3 MG
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
Trial: NCT03569345
Drug: AFXl-assisted ingenol mebutate delivery
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30.
Trial: NCT01379144
Drug: latanoprost 75 ug
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Trial: NCT01379144
Drug: latanoprost 100 ug
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Trial: NCT01379144
Drug: latanoprost 125 ug
RxNorm normalized name: latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Trial: NCT01902992
Drug: Depiquick Birch (DPG103)
RxNorm normalized name: BIRCH TRITERPENES
DrugBank: Birch bark extract (DB16536)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01379144
Drug: latanoprost 50 ug
RxNorm normalized name: LATANOPROST 50 ug in 1 mL OPHTHALMIC SOLUTION
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Trial: NCT01702493
Drug: Tab SRT2104 fast release
RxNorm normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New 250 mg SRT2104 mesylate salt fast release tablet
Trial: NCT02368561
Drug: Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)
RxNorm normalized name: Synvisc Injectable Product
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
Trial: NCT02711241
Drug: Dipyrone
RxNorm normalized name: Dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram by slow IV infusion
Trial: NCT02711241
Drug: Papaverine
RxNorm normalized name: Papaverine
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg by slow intravenous infusion
Trial: NCT00120757
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04267601
Drug: Anagliptin
RxNorm normalized name: Anagliptin
DrugBank: Anagliptin (DB12417)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anagliptin treatment for 24weeks